The susceptibilities of 123 clinically isolated strains of Xanthomonas maltophilia to six fluoroquinolones (clinafloxacin, PD 131628, PD 138312, PD 140248, ciprofloxacin, and ofloxacin) were examined by microdilution MIC methodology. Clinafloxacin and PD 131628 were the most active compounds tested (MICs for 50% of the strains tested [MIC50s] of 0.5 and 1.0 ,ug/ml and MIC90s of 2.0 and 4.0 ,ug/ml, respectively). PD 138312, PD 140248, ciprofloxacin, and ofloxacin were less active, with MIC50s ranging from 4.0 to 8.0 ,ug/ml and MIC90s of 16.0 ,ug/ml for all four compounds. Only clinafloxacin and PD 131628 were active against ciprofloxacinresistant strains, with MIC50s of 0.5 and 1.0 ,ug/ml and MIC90s of 2.0 and 4.0 ,ug/ml, respectively.
Infections caused by Xanthomonas maltophilia are increasingly encountered, especially in patients with compromised host defense mechanisms (10, 11, 17) . The problem is further complicated by the inherently resistant nature of this species, which is due to a combination of permeability defects and ,B-lactamase production (3, 10, 11, 13, 17) . Of commonly used antimicrobial agents, only trimethoprim-sulfamethoxazole has been found to be consistently active in vitro against this organism (10, 17) . Available quinolones such as ciprofloxacin and ofloxacin are marginally active, with MICs for susceptible isolates clustering around the breakpoint (1, 4, 9, (12) (13) (14) . Clinafloxacin (CI-960, PD 127391) and PD 131628 (the active component of the prodrug CI-990) are two new fluoroquinolones with improved activity against gram-positive cocci, gramnegative nonfermenters, and anaerobes (5, 6, 8, 9, 12, 16) . This study compared the activities of clinafloxacin, PD 131628, two other experimental broad-spectrum fluoroquinolones (PD 138312 and PD 140248) (2, 7), ciprofloxacin, and ofloxacin against 123 clinical isolates of X maltophilia.
Most clinical isolates (85%) were from different patients at Hershey Medical Center and University Hospitals of Cleveland and were collected over a 3-year period. The remainder were obtained from sources listed in the Acknowledgments and were isolated over a 6-year period. All strains were reidentified and MIC studies performed at Hershey Medical Center. Strains were identified by standard methods (10) Suscep- tibility breakpoints for ciprofloxacin (2.0 ,ug/ml) and ofloxacin (4.0 ,ug/ml) were those recommended by the National Committee for Clinical Laboratory Standards for members of the family Enterobacteriaceae (15). Breakpoints for the other four compounds were all 2.0 pug/ml, on the basis of preliminary data for members of the family Enterobacteriaceae (2). It should be noted, however, that no definitive quinolone susceptibility breakpoints are available for X maltophilia.
The results of MIC testing are presented in Tables 1 and 2 MIC results for all quinolones analyzed according to resistance to ciprofloxacin (taken as >2.0 pug/ml) are presented in susceptible to clinafloxacin and to PD 131628. MIC50s for the latter group were 0.125 and 0.25 ,g/ml and MIC90s were 0.5 and 0.5 ,ug/ml for the respective compounds. Lower MICs of all other quinolones tested were observed when strains for which ciprofloxacin MICs were s2.0 ,ug/ml were analyzed separately, with .92% susceptible to the four compounds, and M'C50 and MIC90 ranges of 1.0 to 2.0 and 2.0 to 4.0 jig/ml, respectively.
The results of the current study indicate that clinafloxacin and PD 131628 yielded the greatest overall activity against X. maltophilia compared with the four other quinolones tested. Activity was greatest in strains for which ciprofloxacin MICs were s2.0 ,ug/ml. Clinafloxacin and PD 131628 are two new experimental fluoroquinolones with expanded activity against gram-positive and gram-negative organisms, including members of the family Enterobacteriaceae, Streptococcus pneumoniae, and some anaerobes (5, 6, 9, 12, 16) . This study confirms the increased activity against X. maltophilia reported by other workers (5, 6, 8, 16) . In view of the inherent resistance of X. maltophilia strains to most classes of antimicrobial agents (3, 10, 11, 13, 17) , clinafloxacin and PD 131628 may represent additional drugs which may be useful in treatment of infections caused by these organisms.
Because of the lack of standardized breakpoints for quinolones (and indeed other antimicrobial agents) in the case of X maltophilia and because of the tendency of MICs to cluster around provisional breakpoints, the results of the current study must be interpreted with caution. Although clinafloxacin and PD 131628 have been shown by us as well as by others (5, 6, 8, 16 ) to yield lower MICs for X maltophilia than those of other quinolones, the significance of these lower MICs requires further clarification. Time-kill studies are required in order to define the precise kill kinetics of X maltophilia strains by the various quinolones. Additionally, we do not know how easily resistant mutants can be selected among strains with MICs at the high end of the susceptible range for the new quinolones tested. Clinical studies will also be necessary in order to support these data.
